

45

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ruben *et al.*

Appl. No. 10/075,446

Filed: February 15, 2002

For: **Keratinocyte Growth Factor-2**

Confirmation No.: 8759

Art Unit: 1636

Examiner: *To be assigned*

Atty. Docket: 1488.036000Q/EKS/PAJ

Second Preliminary Amendment

Commissioner for Patents
Washington, D.C. 20231

Sir:

In advance of prosecution, Applicants submit the following Amendments. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.115 and MPEP § 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with Markings to Show Changes Made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

40035446-06556

Amendments

In the Specification:

Please replace the paragraph beginning at page 18, line 21, with the following paragraph:

Figures 42A-42B show the anti-inflammatory effect of KGF-2 on PAF-induced paw edema.

10035446.06502


Remarks

The specification has been amended in accordance with the formal drawings submitted herewith. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Prompt and favorable consideration of this Amendment is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Peter A. Jackman
Attorney for Applicants
Registration No. 45,986

Date: June 25, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

10075446.06502

Version with Markings to Show Changes Made

The paragraph beginning at page 18, line 21, was amended as follows:

Figures 42A-42B show [Figure 42 shows] the anti-inflammatory effect of KGF-2 on
PAF-induced paw edema.

SKGF_DC1:20763.1

1005446-062502